Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austar LifesciencesAULSF 40 3-1 Month Momentum % is -71.43% as of Sep. 08, 2026. GuruFocus rates AULSF with a GF Score™ of 40/100 and a GF Value™ of $0.03. The stock has 6 warning signs investors should review. Among 839 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 72.11% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-08), Austar Lifesciences's 3-1 Month Momentum % is -71.43%.
The industry rank for Austar Lifesciences's 3-1 Month Momentum % or its related term are showing as below:
AULSF's 3-1 Month Momentum % is ranked worse than 72.11% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: -2
vs AULSF: -71.43
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Austar Lifesciences 3-1 Month Momentum % Related Terms
AULSF vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Austar Lifesciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a 3-1 Month Momentum % of -71.43% as of Sep. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Austar Lifesciences and its competitors. According to the industry distribution chart, Austar Lifesciences ranks #605 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 72.1%.
Is Austar Lifesciences' 3-1 Month Momentum % too high?
Austar Lifesciences' current 3-1 Month Momentum % is -71.43%. Based on the distribution chart, Austar Lifesciences ranks #605 out of 839 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Austar Lifesciences has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #605 out of 839 companies for 3-1 Month Momentum %. This places Austar Lifesciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Austar Lifesciences and its competitors. Austar Lifesciences's current 3-1 Month Momentum % is -71.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current 3-1 Month Momentum % of -71.43%. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 33.3% below its estimated fair value. The current 3-1 Month Momentum % is -71.43%. Austar Lifesciences' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current 3-1 Month Momentum % is -71.43% as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 33.3% below its estimated GF Value™ of $0.03.
Key valuation signals for AULSF:
3-1 Month Momentum %: -71.43%
GF Value™: $0.03 vs. price of $0.02 (33.3% below fair value)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
40GF Score
Get the complete analysis for AULSF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
